Laura J. van 't Veer, PhD

Leader, Breast Oncology Program, and Associate Director, Applied Genomics, UCSF Helen Diller Family Comprehensive Cancer Center
Principal Investigator, Bay Area Breast Cancer SPORE
Angela and Shu Kai Chan Endowed Chair in Cancer Research

vantveerl@cc.ucsf.edu

Phone: (415) 476-6023
Box 0808, UCSF
San Francisco, CA 94143-0808

View on UCSF Profiles

Education

University of Amersterdam, Faculty of Mathematics and Natural Sciences, B.Sc and M.Sc, 1976-1984, Biology, Molecular Oncology
University of Leiden, Leiden University Medical Center, Dept. of Clinical Oncology, PhD, 1984-1989, Oncogene Activation and Tumorigenesis

Professional Experience

• 1993-present
  Molecular Biologist, Clinical Molecular Geneticist, Group Leader Molecular Pathology, Dept. of Pathology and Division of Experimental Therapy, The Netherlands Cancer Institute
• 1995-2005
  Head DNA-diagnostic Laboratory of the Family Cancer Clinic, The Netherlands Cancer Institute
• 1997-2003
  Head Family Cancer Clinic, The Netherlands Cancer Institute
• 2002-2010
  Honorary staff member, Department of Surgery, Leiden University Medical Center, The Netherlands
• 2004-2007
  Chief Operating Officer, Agendia BV, Amsterdam (part-time)
• 2007
  Chief Research Officer, Agendia BV, Amsterdam (part-time)
• 2007-2010
  Head Division Diagnostic Oncology (ad interim; includes Dept's Pathology, Radiology, Nuclear Medicine, Clinical Chemistry, Family Cancer Clinic), The Netherlands Cancer Institute
• 2008-2009
  Sabbatical Leave (1 yr), UCSF Comprehensive Cancer Center and Lawrence Berkeley National Laboratories - Life Sciences, San Francisco/Berkeley, USA
• 2010-present
  Professor, Laboratory Medicine, University of California, San Francisco
• 2011-present
  Angela and Shu Kai Chan Endowed Chair in Cancer Research, Department of Laboratory Medicine, University of California, San Francisco

Honors & Awards

• 2005
  IARC Medal of Honor, Lyon, France
• 2006
  Van der Scheuren award lecture for European Breast Cancer Research, EBCC5
• 2007
  ESMO Lifetime Achievement Award for Translational Research in Breast Cancer
• 2007, 2008
  Breast Cancer Research Fund (BCRF-Pink Ribbon US) grant award
• 2009
  First Annual Harry and Edith Gladstein Award, Indiana University, School of Medicine

Selected Publications

1. Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van 't Veer LJ. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. 2010 Apr; 120(3):655-61.
   View on PubMed
2. Broeks A, Braaf LM, Wessels LF, van de Vijver M, De Bruin ML, Stovall M, Russell NS, van Leeuwen FE, Van 't Veer LJ. Radiation-associated breast tumors display a distinct gene expression profile. Int J Radiat Oncol Biol Phys. 2010 Feb 1; 76(2):540-7.
   View on PubMed
3. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerød A, Russnes HE, Foekens JA, Reis-Filho JS, van 't Veer L, Richardson AL, Børresen-Dale AL, Campbell PJ, Futreal PA, Stratton MR. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009 Dec 24; 462(7276):1005-10.
   View on PubMed
4. Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJ, van 't Veer LJ. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol. 2010 Apr; 21(4):717-22.
   View on PubMed
5. Linn SC, Van 't Veer LJ. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer. 2009 Sep; 45 Suppl 1:11-26.
   View on PubMed
6. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van 't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LF. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res. 2008; 10(6):R93.
   View on PubMed
7. Molloy T, van 't Veer LJ. Recent advances in metastasis research. Curr Opin Genet Dev. 2008 Feb; 18(1):35-41.
   View on PubMed
8. Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB, Van 't Veer LJ. The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat. 2008 Jan; 107(2):243-8.
   View on PubMed
9. Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, Van Leeuwen FE, Van 't Veer LJ. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res. 2007; 9(2):R26.
   View on PubMed
10. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006 Oct; 3(10):540-51.
    View on PubMed
11. Ruijs MW, Verhoef S, Wigbout G, Pruntel R, Floore AN, de Jong D, van T Veer LJ, Menko FH. Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation. Fam Cancer. 2006; 5(2):169-74.
    View on PubMed
12. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 1; 23(31):7804-10.
    View on PubMed
13. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005 Aug; 5(8):591-602.
    View on PubMed
14. van 't Veer L. Laura van 't Veer, PhD: bringing tumor gene profiles into the clinic. Interview. JAMA. 2004 Aug 11; 292(6):675.
    View on PubMed
15. Voskuil DW, Bosma A, Vrieling A, Rookus MA, van 't Veer LJ. Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat. 2004 Apr; 84(3):225-33.
    View on PubMed
16. Schmidt MK, van Leeuwen FE, Klaren HM, Tollenaar RA, van 't Veer LJ. [Genetic research with stored human tissue: a coding procedure with optimal use of information and protection of privacy]. Ned Tijdschr Geneeskd. 2004 Mar 20; 148(12):564-8.
    View on PubMed
17. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15; 22(6):1055-62.
    View on PubMed
18. Szabo CI, Schutte M, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR, Durocher F, Oldenburg RA, Wasielewski M, Odefrey F, Thompson D, Floore AN, Kraan J, Klijn JG, van den Ouweland AM, Wagner TM, Devilee P, Simard J, van 't Veer LJ, Goldgar DE, Meijers-Heijboer H. Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles? Cancer Res. 2004 Feb 1; 64(3):840-3.
    View on PubMed
19. Weigelt B, Bosma AJ, van 't Veer LJ. Expression of a novel lacrimal gland gene lacritin in human breast tissues. J Cancer Res Clin Oncol. 2003 Dec; 129(12):735-6.
    View on PubMed
20. Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van 't Veer LJ. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer. 2003 Apr 7; 88(7):1091-4.
    View on PubMed

View on UCSF Profiles